ONC-392,Pembrolizumab
biontech,Merck
['sclc', 'nsclc', '$bntx', 'biontech']
$bntx biontech and oncoc4 present positive phase 1/2 data for antibody candidate bnt316/onc-392 in hard-to-treat nsclc at asco
Options trader. Market-news. Nothing posted constitutes as advice. Do your own diligence.